"We're entering an era of more trauma-informed care, and trying to be sensitive to the fact that some of these invasive procedures can be a trigger for people because they're in that moment of feeling helpless and they don't have really a lot of control over the situation," says Heidi J. Rayala, MD.
"If you don't do a repeat curve assessment with each series of injections, you're possibly going to be missing the best location to do the injections," says Landon Trost, MD.
"The genomics assay was using biopsy tissue to help patients make decisions for the treatment choices. We also tested the effect of the assay on provider choice," says Adam B. Murphy, MD, MBA, MSCI.
"There are a lot of questions and issues regarding [topics] like body image and sexual function, and things like that, that also, being a woman in this role, I feel like they feel comfortable asking me those questions," says Bree Duncan, RN, BSN.
"Then [we] also started looking at somatic testing, because if you only stop at germline testing, you miss another 50% of patients who would have somatic alterations who have resistant prostate cancer," says Neal D. Shore, MD, FACS.
"In 2021, we started collecting data on opioids prescribed at discharge to see whether or not patients did or did not get prescribed opioids," says Katherine Wang, MD.
Experts on prostate cancer outline the best candidates for rectal spacing and outline factors that influence rectal spacer placement.
Prostate cancer specialists provide insights on stereotactic body radiation therapy (SBRT) and hypofractionation and their relationship to optimal rectal spacing.
"My goal is to always meet them there in clinic, and then just start that relationship, in a sense of, I'm there for whatever they need," says Bree Duncan, RN, BSN.
“Private equity allows an opportunity to provide improved scale with large organization,” says Scott B. Sellinger, MD, FACS.
“[Although] not yet ready for prime time, ctDNA is being investigated as a very promising non-invasive plasma biomarker of invasive or advanced-stage upper tract urothelial carcinoma,” says Heather L. Huelster, MD.
"The viability and survivability of practices is in jeopardy," says Bradley Gill, MD.
"I think the take-home message is that surgery is safe, even for these challenging surgical cases after this therapy," says Jason Scovell, MD.
"In the study, when taking into account other factors, such as the socioeconomic factors that are available to us in the NCDB, we find that African American and Hispanic patients are about 20% less likely to receive immune checkpoint inhibition for advanced RCC," says Solomon L. Woldu, MD.
"One of the biggest surprises was just how ubiquitous prescribing narcotics in all phases were, from intraoperatively to the PACU to postoperatively," says Aaron A. Laviana, MD, MBA.
“The efficacy analysis for all patients based upon a central pathology review revealed a complete response at any time point of 75.7%,” says Mark D. Tyson, MD, MPH.
Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.
Experts on prostate cancer discuss the risks, complications, and safety considerations for patients with prostate cancer who are considering radiation therapy.
"Specifically when we stratified by tertiles, we saw that at 15 years there was a significant difference in cancer-specific survival for those who had a high MMAI score vs lower MMAI scores," says Eric Li, MD.
"All forms of cancer start out by genetic changes in the DNA that cause cancer, so genetic testing becomes very important," says William J. Catalona, MD.
"We're one of the first to look at hypogonadism, or low testosterone, as a marker for both frailty and also as a biomarker for how these patients do after surgery," says Daniel Greenberg, MD.
"The Inflation Reduction Act has changed the landscape, and we really still don't understand what those implications are going to be," says Mara R. Holton, MD.
"We need improved efficiency. Part of that is being as optimal in our settings and in our techniques that we can," says Smita De, MD, PhD.
"We found that about 25% of these men had either sought treatment for a men's health issue or a sexual issue or had wanted to seek care," says Daniel Greenberg, MD.
Laura Bukavina, MD, MPH, offers a preview of noteworthy bladder and kidney cancer research to be presented at this year's Society of Urologic Oncology Annual Meeting.
In this installment, expert Paul E. Dato, MD, discusses the value of a multidisciplinary team in managing patients with mCRPC and considers how his institution ensures patients receive best available therapy.
"We knew that the MS or momentary squeeze pump, originally designed at AMS was a fine device, but it did have some issues. We thought we could make it even better," says Ronald A. Morton, MD.
Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology.
"What we found is that overall, it was relatively effective at providing advice to patients on these pretty commonly encountered questions," says Sharath Reddy, MD.
“Health literacy pushed people towards active surveillance, which I thought was an interesting finding,” says Adam B. Murphy, MD, MBA, MSCI.
